Get started
BIOGAIA AG SER'B'NPVBIOGAIA AG SER'B'NPVBIOGAIA AG SER'B'NPV

BIOGAIA AG SER'B'NPV

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0GTN chart


Full chart

0GTN upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪10.72 B‬ SEK
Dividend yield (indicated)
6.51%
Price to earnings Ratio (TTM)
31.7
Basic EPS (TTM)
3.3 SEK
Net income (FY)
‪365.35 M‬ SEK
Revenue (FY)
‪1.30 B‬ SEK
Shares float
‪87.22 M‬
Beta (1Y)
0.17

Employees


Employees (FY)
210
Change (1Y)
−2 −0.94%
Revenue / Employee (1Y)
‪609.36 K‬ SEK
Net income / Employee (1Y)
‪171.72 K‬ SEK

About BIOGAIA AB SER. B


Sector
Health Technology
CEO
Theresa Agnew
Headquarters
Stockholm
Website
biogaia.com
Founded
1990
ISIN
SE0017769995
FIGI
BBG00NRVWCT8
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, oral rehydration solutions, digestive health tablets, and also royalties pertaining to pediatric products. The Adult Health segment include gut health tablets, oral health products, and offers cultures as an ingredient in a licensee's dairy product. The Other segment consists royalties from the development projects, and revenue from packaging solutions. The company was founded by Jan Annwall and Peter Michael Rothschild in 1990 and is headquartered in Stockholm, Sweden.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0GTN news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0GTN is 105.6 SEK — it has decreased by −0.47% in the past 24 hours. Watch BIOGAIA AG SER'B'NPV stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSIN exchange BIOGAIA AG SER'B'NPV stocks are traded under the ticker 0GTN.
0GTN stock has fallen by −4.54% compared to the previous week, the month change is a −0.47% fall, over the last year BIOGAIA AG SER'B'NPV has showed a 0.57% increase.
We've gathered analysts' opinions on BIOGAIA AG SER'B'NPV future price: according to them, 0GTN price has a max estimate of 150.00 SEK and a min estimate of 150.00 SEK. Watch 0GTN chart and read a more detailed BIOGAIA AG SER'B'NPV stock forecast: see what analysts think of BIOGAIA AG SER'B'NPV and suggest that you do with its stocks.
0GTN reached its all-time high on May 21, 2024 with the price of 136.5 SEK, and its all-time low was 17.7 SEK and was reached on Jan 29, 2010. View more price dynamics on 0GTN chart.
See other stocks reaching their highest and lowest prices.
0GTN stock is 1.53% volatile and has beta coefficient of 0.17. Track BIOGAIA AG SER'B'NPV stock price on the chart and check out the list of the most volatile stocks — is BIOGAIA AG SER'B'NPV there?
Today BIOGAIA AG SER'B'NPV has the market capitalization of ‪10.72 B‬, it has decreased by −1.94% over the last week.
Yes, you can track BIOGAIA AG SER'B'NPV financials in yearly and quarterly reports right on TradingView.
BIOGAIA AG SER'B'NPV is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
0GTN earnings for the last quarter are 0.58 SEK per share, whereas the estimation was 0.64 SEK resulting in a −8.66% surprise. The estimated earnings for the next quarter are 0.57 SEK per share. See more details about BIOGAIA AG SER'B'NPV earnings.
BIOGAIA AG SER'B'NPV revenue for the last quarter amounts to ‪304.00 M‬ SEK, despite the estimated figure of ‪324.90 M‬ SEK. In the next quarter, revenue is expected to reach ‪333.40 M‬ SEK.
0GTN net income for the last quarter is ‪36.60 M‬ SEK, while the quarter before that showed ‪111.01 M‬ SEK of net income which accounts for −67.03% change. Track more BIOGAIA AG SER'B'NPV financial stats to get the full picture.
BIOGAIA AG SER'B'NPV dividend yield was 1.88% in 2023, and payout ratio reached 52.52%. The year before the numbers were 1.74% and 39.17% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 14, 2024, the company has 210.00 employees. See our rating of the largest employees — is BIOGAIA AG SER'B'NPV on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOGAIA AG SER'B'NPV EBITDA is ‪483.84 M‬ SEK, and current EBITDA margin is 35.76%. See more stats in BIOGAIA AG SER'B'NPV financial statements.
Like other stocks, 0GTN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOGAIA AG SER'B'NPV stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOGAIA AG SER'B'NPV technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOGAIA AG SER'B'NPV stock shows the sell signal. See more of BIOGAIA AG SER'B'NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.